EZH2作为抗肿瘤免疫治疗靶点的研究进展.pdfVIP

生物技术通报 ·综述与专论· BIOTECHNOLOGY BULLETIN ( ) 2015, 31 1 :29-32 EZH2 作为抗肿瘤免疫治疗靶点研究进展 李倩  王艳林  （三峡大学医学院 三峡大学分子生物学研究所，宜昌 443002） 摘 要 ： 多梳蛋白复合体（PcG）的核心亚基zeste 基因增强子同源物2（Enhancer of zeste homolog2，EZH2）是一种组蛋白 甲基转移酶，参与维持细胞密度、干细胞多能性、细胞周期调节等重要的生理作用。研究发现，EZH2 在多种肿瘤组织中高表达， 是促进肿瘤发生和发展的致癌因子。由于EZH2 在正常组织中低表达或者不表达，使其新近被鉴定为一种肿瘤相关抗原。 已经在 EZH2 蛋白分子中鉴定出多条特异性抗原肽，这些抗原肽能激发机体免疫细胞对EZH2 表达异常增高肿瘤细胞的杀伤活性。上述研 究提示，EZH2 可能是一种新的抗肿瘤治疗分子靶点，并在肿瘤免疫治疗中具有潜在的应用价值。就该领域的最新研究进展作一简 要综述。 关键词 ： EZH2 ；分子靶点 ；抗肿瘤免疫 ；肿瘤相关抗原 DOI ：10.13560/ki.biotech.bull.1985.2015.01.004 - Research Progress in EZH2 as a Target for Anti tumor Immunotherapy Li Qian Wang Yanlin （Medical College ，Institute of Molecular Biology ，Three Gorges University ，Yichang 443002 ） Abstract: EZH2（enhancer of Zeste homolog2）, the core subunit of polycomb group protein complex（PcG）, is a histone methyltransferase which involves in cell density maintenance, stem cell pluripotent, cell cycle regulation and other important physiological roles. The study has found that EZH2 is over-expressed in many tumor tissues and can be used as a carcinogen to promote tumorigenesis. Since EZH2 has been proved to be non- or low-expressed in normal tissues, it has recently been identified as a tumor-associated antigen. Multiple antigen peptides derived from the EZH2 protein have been identified and their ability in stimulating the killing activity of immune cells against the tumor cells with over-expressed EZH2 has been proved. These studies indicate that EZH2 could be a new molecular target for